Many pharmaceutical companies through acquisitions enter in vitro diagnostic reagents market. In April, Roche spend $ 450 million acquisition of IQuum company, IQumm focused on developing products for the molecular diagnostics market. Molecular diagnosis is the primary diagnostic method for prenatal diagnosis. It is more specific and precision than other biochemical diagnosis. In September, Beijing Leadman acquisition of a stake in Desai Desai diagnostic systems and diagnostic products. Germany Desai is headquartered in is is a large multinational professional development, production and marketing of in vitro diagnostic products.
With the high incidence of the disease, the aging population increases, economic development, as well as higher demand of medical services, in vitro diagnostics market will continue to expand. Although the basic realization of our current biochemical diagnosis localization, but in immunodiagnostic and molecular diagnostic high-end technology, still largely dependent on foreign products. Recently, in vitro diagnostic industry domestic laws and regulations were revised, the in vitro diagnostics industry chain all kinds of participants, independent laboratories need to clear the opportunities and challenges they face. Vitro Diagnostics has developed rapidly in tumor diagnosis, prenatal diagnosis, genetic disease testing, infectious disease detection, related companies need to keep up with market demand quickly meet the needs of clinical applications. In addition, many of the Chinese in vitro diagnostic companies began to try to open up overseas markets, Europe and the United States need to understand the registration regulations and market access standards.
Contact Us
Postal Address:Wuhan Hi-tech Medical Devices Park, Building B11, #818 Gaoxin Road, Donghu Hi-Tech Development Area, Wuhan, Hubei Province 430206, P.R.China
Tel: +86-27-87582341
Fax: +86-27-87196150
Homepage: CUSABIO
没有评论:
发表评论